secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-11-26T23:59:59+00:00
Accession:  0001493152-25-025177
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
------------------------------------------------------------------------------

- Nasdaq notified Akari on Nov 24, 2025 that ADS closing bid price below $1.00 for 30 consecutive business days.
- Company has 180 calendar days (until May 25, 2026) to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not cured by May 25, 2026, Akari may be eligible for an additional 180-day period if other listing standards are met.
- Failure to regain compliance could result in delisting of ADSs from Nasdaq Capital Market.
- Akari may consider an ADS ratio change to address the bid price deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225025177/0001493152-25-025177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225025177/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-025177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer